<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847897</url>
  </required_header>
  <id_info>
    <org_study_id>0217-16-RMB</org_study_id>
    <nct_id>NCT02847897</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser Treatment on Vaginal Elasticity.</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser for the Treatment of Vaginal Prolapse in Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to assess the safety and efficacy of CO2 AcuPulse laser treatment in
      patients with vaginal prolapse. Eligible subjects will receive 3 treatment sessions, 4 weeks
      apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a screening visit, eligible subjects will be enrolled into the study. Each subject
      will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months
      following the last treatment.

      Further demographic information and patient history will be obtained from the subjects`
      electronical files.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in vaginal prolapse symptoms as measured by VHI score at 3 months follow-up visit compared to baseline.</measure>
    <time_frame>8 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Prolapse symptoms improvement as evaluated by the investigator using VHI score at 1 and 6 months follow up visits compared to baseline</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Prolapse symptoms improvement as evaluated by the subject using Visual Analogue Scale (VAS) at 1, 3 and 6 months follow up visits compared to baseline</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Improvement in sexual function as evaluated by the subject Female Sexual Function Index (FSFI) at 1, 3 and 6 months follow up visits compared to baseline</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Improvement in urinary incontinence as evaluated by subject Incontinence Quality of Life Questionnaire (I-QOL) at 1, 3 and 6 months follow up visits compared to baseline.</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Improvement in prolapse grade at 1, 3 and 6 months follow up visits compared to baseline</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Subject satisfaction with the treatment sing a 5-point Likert scale at baseline and at 1, 3 and 6 months follow up visits</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Subject self- assessment of downtime related to procedure - the period of time following the procedure during which the subject felt uncomfortable/unwilling or unable to have sexual intercourse</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Subject assessment of pain and discomfort that is procedure related using a visual a Pain Visual Analogue Scale (VAS), evaluated at each treatment.</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE's) and serious adverse events (SAE's)</measure>
    <time_frame>8 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Exposure Laser</condition>
  <arm_group>
    <arm_group_label>CO2 AcuPulse Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 AcuPulse Laser</intervention_name>
    <description>Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.</description>
    <arm_group_label>CO2 AcuPulse Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Healthy post-menopausal women as defined by one of the following: A. ≥ 40 years old, last
        spontaneous menstrual bleeding occurred at least ≥ 12 months prior to screening B. ≥ 45
        years old, does not remember the date of last spontaneous menstrual bleeding and provides
        lab results showing that the follicle-stimulating hormone (FSH) level is &gt; 40 IU/L C.
        Underwent a hysterectomy without oophorectomy and provides lab results showing that serum
        FSH levels &gt; 40IU/L D. Underwent bilateral oophorectomy at least 12 weeks prior to
        screening

          -  Presence of one or more of the prolapse related symptoms (e.g. dryness, itching,
             burning, dysuria or dyspareunia)

          -  At least 10 subjects of the sample will have symptoms of urinary stress incontinence
             (Stamey classification Grade =1)

          -  Negative urine analysis

          -  Normal Papanicolaou (PAP) test from the recent year

          -  Sexually active (having sex at least once a month) or wishing to maintain an active
             sexual life

          -  Able and willing to comply with the treatment/follow-up schedule and requirements

        Exclusion Criteria:

          -  Vaginal Health Index Score (VHIS) &lt; 5

          -  Active genital infection

          -  Subject presenting abnormal PAP result from the last three years with any of the
             following findings according to the Bethesda System (2001) classification:

        A. Atypical Squamous Cells of Undetermined Significance (ASCUS with positive human
        papilloma virus (HPV) High Risk Positive B. Atypical Squamous Cells-cannot exclude high
        grade squamous intraepithelial lesion C. Atypical Glandular Cells (Endocervical,
        Endometrial not otherwise specified) D. Low Grade squamous intraepithelial lesion (LSIL) E.
        High Grade squamous intraepithelial lesion (HSIL) F. Carcinoma

          -  Systemic steroids use within the last 3 months

          -  Systemic hormonal replacement therapies within the last 3 months

          -  Local hormonal replacement therapies within last month

          -  Vaginal lubricants within 7 days prior to enrollment

          -  Recurring urinary tract infection or recurring infection of genital herpes or candida
             (&gt; 2 episodes in the recent year)

          -  Pelvic organ prolapse (POP) &gt;II according to the pelvic organ prolapse quantification
             system

          -  Transvaginal mesh implant

          -  Serious systemic disease or any chronic condition that could interfere with study
             compliance

          -  Taken part in a clinical trial within 30 days prior to screening.

          -  Any other reason that, in the opinion of the investigator, prevents the subject from
             participating in the study or compromise the subject safety
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Lowenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roy Lauterbach, MD</last_name>
    <phone>972529432416</phone>
    <email>r_lauterbach@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Lauterbach, MD</last_name>
      <phone>0529432416</phone>
      <email>r_lauterbach@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Dr. Roy Lauterbach</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

